Insider Transactions in Q2 2022 at Royalty Pharma PLC (RPRX)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2022
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
903
+3.34%
|
$37,023
$41.52 P/Share
|
|
Jun 30
2022
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
903
+2.75%
|
$37,023
$41.52 P/Share
|
|
Jun 29
2022
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Direct |
30,000
-6.64%
|
$1,260,000
$42.17 P/Share
|
|
Jun 24
2022
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,328
+20.05%
|
-
|
|
Jun 24
2022
|
David C Hodgson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,328
+50.0%
|
-
|
|
Jun 24
2022
|
Errol B Desouza Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,328
+10.04%
|
-
|
|
Jun 24
2022
|
Ted W Love Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,328
+17.81%
|
-
|
|
Jun 24
2022
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,328
+16.94%
|
-
|
|
Jun 24
2022
|
Catherine M. Engelbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,328
+19.9%
|
-
|
|
Jun 24
2022
|
Gregory Norden Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,328
+10.04%
|
-
|
|
Jun 24
2022
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
23,333
-50.0%
|
$1,003,319
$43.19 P/Share
|
|
Jun 08
2022
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
100,000
-9.8%
|
$4,100,000
$41.56 P/Share
|
|
May 27
2022
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
75,000
-6.84%
|
$3,075,000
$41.08 P/Share
|
|
May 27
2022
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
13,974
-3.15%
|
$558,960
$40.77 P/Share
|
|
May 26
2022
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
86,026
-16.23%
|
$3,441,040
$40.21 P/Share
|
|
May 23
2022
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
100,000
-15.87%
|
$4,000,000
$40.27 P/Share
|
|
May 20
2022
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Direct |
123,696
-21.5%
|
$4,824,144
$39.28 P/Share
|
|
May 19
2022
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Direct |
26,304
-4.37%
|
$1,052,160
$40.09 P/Share
|
|
May 19
2022
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
75,000
-6.41%
|
$3,000,000
$40.44 P/Share
|
|
May 16
2022
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
23,333
-33.33%
|
$909,987
$39.85 P/Share
|
|
May 11
2022
|
Marshall Urist EVP, Research & Investments |
BUY
Conversion of derivative security
|
Direct |
70,000
+50.0%
|
-
|
|
Apr 14
2022
|
Legorreta Pablo G. CEO, Chairman of the Board |
SELL
Other acquisition or disposition
|
Direct |
350,000
-84.58%
|
-
|
|
Apr 14
2022
|
Legorreta Pablo G. CEO, Chairman of the Board |
SELL
Other acquisition or disposition
|
Indirect |
462,031
-100.0%
|
-
|